Brain Peptides: What a Psychiatrist Wants You to Know

Talkiatry psychiatrists are hearing more and more questions about brain peptides. Social media influencers talk about "peptide therapy" like it’s the next breakthrough in mental health. But when you look past the marketing, there’s a wide gap between naturally occurring neuropeptides and injectable peptide products.

"Brain peptide therapy" is not a recognized psychiatric treatment category; the term is commercial, not clinical. Neuropeptides are real molecules that regulate almost all bodily and cognitive functions. But the products marketed as "brain peptide therapy" have not been proven safe or effective for any psychiatric treatment,¹ and no peptide has cleared the FDA approval process for depression, anxiety, ADHD, or any other diagnosis.

This article breaks down what the science actually shows, and what a psychiatrist recommends instead.

What are brain peptides?

Brain peptides, also called neuropeptides, are short chains of amino acids your brain produces naturally. They act as chemical messengers, regulating functions like mood, stress, pain, and sleep.  

Your brain makes dozens of neuropeptides, each with a different job.⁸ Some of the most studied include:

• Oxytocin: social bonding and trust

• Neuropeptide Y (NPY): stress resilience and anxiety regulation; widely distributed throughout the central nervous system¹¹

• Substance P: pain processing and inflammation

• Endorphins: pain relief and reward

• Orexin: sleep-wake cycle

Why are people interested in peptides for mental health?

Interest in brain peptides has grown quickly, with online searches for "peptide therapy" rising sharply in recent years.

Three factors drive this trend. First, GLP-1 drugs like semaglutide made "peptide" a household word. Second, influencers and biohacking communities promote peptides. Third, some people are looking for alternatives to traditional psychiatric medication.

But knowing that a molecule matters in the brain is not the same as knowing how to deliver it safely, in the right dose and to the right place.

What does the evidence actually show?

The evidence for brain peptides in psychiatry ranges from nonexistent to very early-stage. None of the popular peptides have the kind of data that FDA-approved treatments do.

BPC-157

BPC-157, marketed to promote healing, is the most hyped brain peptide online. It's completed no human clinical trials for any psychiatric condition;⁴ all the evidence cited by promoters comes from rodent studies. In 2023, the FDA classified BPC-157 as Category 2, meaning it presents "significant safety concerns."²

Selank

Selank was developed in Russia as a synthetic version of tuftsin, which stimulates the body’s immune system. Some researchers have explored its effects on anxiety, but the studies are small and not widely replicated.⁵

Oxytocin

Oxytocin is the most studied neuropeptide for psychiatric use. A 2019 systematic review of randomized controlled trials found no significant difference in anxiety or depression outcomes with intranasal oxytocin.⁶ Research into whether it might enhance psychotherapy is still preliminary.⁶

Neuropeptide Y (NPY)

Research into NPY, linked to appetite and metabolism, is still at the earliest stage. One NIH-funded study tested intranasal NPY in patients with PTSD to determine a safe dose, not to test efficacy.⁷ There isn’t enough evidence yet to know whether it works.

{{BLOG_AD}}

Are brain peptides safe?

Per the FDA, the safety profile of most commercial brain peptides is unknown. When it classified 17 peptides as presenting "significant safety concerns," the FDA noted it "has not identified any human exposure data" for many of them.²  

What’s more, independent testing of unregulated products has found the wrong peptides, incorrect doses, bacterial contamination, and heavy metals.³ In April 2026, the American Medical Association published guidance warning that many injectable peptides haven’t been thoroughly tested or reviewed by the FDA.¹⁰

Why haven't neuropeptide discoveries become treatments?

The science of neuropeptides is real; the challenge is turning that science into something that's safe to use. Four factors explain most of the gap:  

• Most peptides cannot cross the blood-brain barrier; when you swallow or inject a peptide, it doesn’t easily reach the brain.  

• Peptides break down fast, making it hard to maintain the steady levels required for a treatment.  

• Neuropeptide receptors are complex, so targeting one pathway without disrupting others is difficult.

• Intranasal delivery is inconsistent; nasal sprays can bypass the blood-brain barrier, but only partially.⁹

Think of it this way: serotonin's role in mood has been known for decades, but it took years of research before SSRIs became reliable treatments. Neuropeptide science is still in the "we know these molecules matter" phase, not the "we can safely use them as medicine" one.

What treatments are actually proven?

The goals driving peptide curiosity (better mood, less anxiety, sharper focus) are achievable with approaches backed by large-scale evidence.

For depression, SSRIs have been studied in hundreds of randomized controlled trials with tens of thousands of participants. A 2018 study in The Lancet reviewed 21 antidepressants and confirmed they work.¹¹ Plus, antidepressants have been tracked for decades after hitting the market.

For anxiety, SSRIs, SNRIs, buspirone, beta-blockers, and therapy (including CBT and exposure therapy) all have strong evidence.¹²

For ADHD, stimulant and non-stimulant medications have decades of research documenting their effects on focus and executive function.

For PTSD, the SSRIs sertraline and paroxetine are FDA-approved, and trauma-focused therapy has strong evidence.

The bottom line

Neuropeptides are real brain molecules involved in mood, stress, and cognition. But the products sold as "brain peptide therapy" haven’t cleared the bar that FDA-approved treatments have: large-scale human trials, safety monitoring, and regulatory review.

If you’re experiencing symptoms of anxiety, depression, ADHD, or another condition, a psychiatrist can help you find a treatment backed by evidence.

Getting started with Talkiatry

Talkiatry is a national psychiatry practice that makes it easier to get care from doctors who listen. Start by answering a few questions online, then get matched with a psychiatrist based on your needs. From there, you can schedule a visit, often within days, and meet with your provider from home. First visits are 60 minutes, so there's time to talk through what's going on and build a treatment plan together. Talkiatry is in-network with most major insurers, and you can check your coverage during the free online assessment.

Take our free online assessment

Medical disclaimer and sources

The information in this article is for informational and educational purposes only and should never be substituted for medical advice, diagnoses, or treatment. If you or someone you know may be in danger, call 911 or the National Suicide and Crisis Lifeline at 988 right away.

Sources

1. FDA, “New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products.” June 2026. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products
2. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
3. FDA Warning Letter to USApeptide.com. February 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
4. Fosgerau K, Hoffmann T. “Peptide therapeutics: current status and future directions.” Drug Discovery Today. 20(1):122-128. January 2015. https://www.sciencedirect.com/science/article/pii/S1359644614003997
5. No Western peer-reviewed RCT for Selank in anxiety disorders is registered on ClinicalTrials.gov or indexed in PubMed as of 2026. Selank is not FDA-approved or EMA-approved. This citation reflects verified absence of evidence rather than a single source.
6. De Cagna F, et al. “The Role of Intranasal Oxytocin in Anxiety and Depressive Disorders: A Systematic Review of Randomized Controlled Trials.” Hormones and Behavior. 108:41-51. February 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6361048/
7. Sayed S, et al. “A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder.” International Journal of Neuropsychopharmacology. November 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5795352/
8. Kupcova I, et al. “Anxiety and Depression: What Do We Know of Neuropeptides?” Behavioral Sciences. 12(8):262. July 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9405013/
9. Jülke EM, Beck-Sickinger AG. “Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery.” ScienceDirect. June 2025. https://www.sciencedirect.com/science/article/pii/S0196978125000658
10. American Medical Association. “What doctors want patients to know about injectable peptides.” April 2026. https://www.ama-assn.org/public-health/prevention-wellness/what-doctors-want-patients-know-about-injectable-peptides
11. Cipriani A, et al. “Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.” The Lancet. 391(10128):1357-1366. April 2018. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext
12. National Institute of Mental Health. “Mental Health Medications.” December 2023. https://www.nimh.nih.gov/health/topics/mental-health-medications
13. FDA, “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).” June 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Frequently asked questions

Are any brain peptides FDA-approved for mental health?

No. As of July 2026, no peptide therapy is FDA-approved for any psychiatric condition. Dozens of peptides are FDA-approved for other medical uses, like insulin for diabetes and semaglutide for weight management.¹³ But none are approved for depression, anxiety, ADHD, or any other mental health condition.¹

Can peptides replace antidepressants or ADHD medication?

There’s no evidence for replacing FDA-approved psychiatric medications with peptide therapy. SSRIs, SNRIs, and stimulants have decades of clinical trial data.¹¹ If you’re considering changes to your medication, talk to your psychiatrist first.

What’s the difference between neuropeptides and peptide therapy?

Neuropeptides are molecules your brain makes naturally to regulate mood, stress, and cognition.⁸ "Peptide therapy" refers to injectable or supplement products sold commercially. The existence of natural neuropeptides doesn't mean that commercial peptide products are safe or effective treatments.

What should I ask my psychiatrist about brain peptides?

Ask whether the specific peptide you’re interested in is FDA-approved, what the known risks are, and what proven alternatives exist for your symptoms. A psychiatrist can help you weigh the evidence and find a treatment plan that fits your needs.